1
|
Oesch F, Honarvar N, Fabian E, Berger FI, Landsiedel R. N-vinyl compounds: studies on metabolism, genotoxicity, carcinogenicity. Arch Toxicol 2021; 95:3143-3159. [PMID: 34091723 DOI: 10.1007/s00204-021-03081-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 05/17/2021] [Indexed: 11/29/2022]
Abstract
Several N-vinyl compounds are produced in high volumes and are widely employed in the production of copolymers and polymers used in chemical, pharmaceutical, cosmetic and food industry. Hence, information on their genotoxicity and carcinogenicity is requisite. This review presents hitherto available information on the carcinogenicity and genotoxicity of N-vinyl compounds as well as their metabolism potentially generating genotoxic and carcinogenic derivatives. The genotoxicity and carcinogenicity of the investigated N-vinyl compounds vary widely from no observed carcinogenicity tested in lifetime bioassays in two rodent species (up to very high doses) to carcinogenicity in rats at very low doses in the absence of apparent genotoxicity. Despite of the presence of the vinyl group potentially metabolized to an epoxide followed by covalent binding to DNA, genotoxicity was observed for only one of the considered N-vinyl compounds, N-vinyl carbazole. Carcinogenicity was investigated only for two, of which one, N-vinyl pyrrolidone was carcinogenic (but not genotoxic) and ranitidine was neither carcinogenic nor genotoxic. As far as investigated, neither a metabolically formed epoxide nor a therefrom derived diol has been reported for any of the considered N-vinyl compounds. It is concluded that the information collected in this review will further the understanding of the carcinogenic potentials of N-vinyl compounds and may eventually allow approaching their prediction and prevention. A suggestion how to prevent genotoxicity in designing of N-vinyl compounds is presented. However, the available information is scarce and further research especially on the metabolism of N-vinyl compounds is highly desirable.
Collapse
Affiliation(s)
- F Oesch
- Oesch-Tox Toxicological Consulting and Expert Opinions, 55263, Ingelheim, Germany
| | - N Honarvar
- BASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen am Rhein, Germany
| | - E Fabian
- BASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen am Rhein, Germany
| | - F I Berger
- Regulatory Toxicology of Chemicals, BASF SE, 67056, Ludwigshafen am Rhein, Germany
| | - Robert Landsiedel
- BASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen am Rhein, Germany.
| |
Collapse
|
2
|
Christophoridis C, Nika MC, Aalizadeh R, Thomaidis NS. Ozonation of ranitidine: Effect of experimental parameters and identification of transformation products. THE SCIENCE OF THE TOTAL ENVIRONMENT 2016; 557-558:170-182. [PMID: 27133934 DOI: 10.1016/j.scitotenv.2016.03.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2015] [Revised: 02/16/2016] [Accepted: 03/04/2016] [Indexed: 06/05/2023]
Abstract
This study focuses on the effect of experimental parameters on the removal of ranitidine (RAN) during ozonation and the identification of the formed transformation products (TPs). The influence of pH value, the initial concentrations, the inorganic and the organic matter on RAN's removal were evaluated. Results indicated high reactivity of RAN with molecular aqueous ozone. Initial ozone concentration and pH were proven the major process parameters. Alkaline pH values promoted degradation and overall mineralization. Dissolved organic matter reacts competitively to RAN with the oxidants (ozone and/or radicals), influencing the target compound's removal. The presence of inorganic ions in the matrix did not seem to affect RAN ozonation. A total of eleven TPs were identified and structurally elucidated, with the complementary use of both Reversed Phase (RP) and Hydrophilic Interaction Liquid Chromatography (HILIC) quadrupole time of flight tandem mass spectrometry (Q-ToF-MS/MS). Most of the TPs (TP-304, TP-315b, TP-299b, TP-333, TP-283) were generated by the attack of ozone at the double bond or the adjacent secondary amine, with the abstraction of NO2 moiety, forming TPs with an aldehyde group and an imine bond. Oxidized derivatives with a carboxylic group (TP-315a, TP-331a, TP-331b, TP-299a) were also formed. RAN S-oxide was identified as an ozonation TP (TP-330) and its structure was confirmed through the analysis of a reference standard. TP-214 was also produced during ozonation, through the CN bond rupture adjacent to the NO2 moiety. HILIC was used complementary to RP, either for the separation and identification of TPs with isomeric structures that may have been co-eluted in RPLC or for the detection of new TPs that were not eluted in the RP chromatographic system. Retention time prediction was used as a supporting tool for the identification of TPs and results were in accordance with the experimental ones in both RP and HILIC.
Collapse
Affiliation(s)
- Christophoros Christophoridis
- Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou, Athens 15771, Greece
| | - Maria-Christina Nika
- Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou, Athens 15771, Greece
| | - Reza Aalizadeh
- Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou, Athens 15771, Greece
| | - Nikolaos S Thomaidis
- Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou, Athens 15771, Greece.
| |
Collapse
|
3
|
Olvera-Vargas H, Oturan N, Brillas E, Buisson D, Esposito G, Oturan MA. Electrochemical advanced oxidation for cold incineration of the pharmaceutical ranitidine: mineralization pathway and toxicity evolution. CHEMOSPHERE 2014; 117:644-651. [PMID: 25461930 DOI: 10.1016/j.chemosphere.2014.09.084] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Revised: 09/23/2014] [Accepted: 09/25/2014] [Indexed: 06/04/2023]
Abstract
Ranitidine (RNTD) is a widely prescribed histamine H2-receptor antagonist whose unambiguous presence in water sources appointed it as an emerging pollutant. Here, the degradation of 0.1 mM of this drug in aqueous medium was studied by electrochemical advanced oxidation processes (EAOPs) like anodic oxidation with electrogenerated H2O2 and electro-Fenton using Pt/carbon-felt, BDD/carbon-felt and DSA-Ti/RuO2–IrO2/carbon-felt cells. The higher oxidation power of the electro-Fenton process using a BDD anode was demonstrated. The oxidative degradation of RNTD by the electrochemically generated OH radicals obeyed a pseudo-first order kinetics. The absolute rate constant for its hydroxylation reaction was 3.39 × 109 M−1 s−1 as determined by the competition kinetics method. Almost complete mineralization of the RNTN solution was reached by using a BDD anode in both anodic oxidation with electrogenerated H2O2 and electro-Fenton processes. Up to 11 cyclic intermediates with furan moiety were detected from the degradation of RNTD, which were afterwards oxidized to short-chain carboxylic acids before their mineralization to CO2 and inorganic ions such as NH4+, NO3− and SO42−. Based on identified products, a plausible reaction pathway was proposed for RNTD mineralization. Toxicity assessment by the Microtox® method revealed that some cyclic intermediates are more toxic than the parent molecule. Toxicity was quickly removed following the almost total mineralization of the treated solution. Overall results confirm the effectiveness of EAOPs for the efficient removal of RNTD and its oxidation by-products from water.
Collapse
Affiliation(s)
- Hugo Olvera-Vargas
- Université Paris-Est, Laboratoire Géomatériaux et Environnement (LGE), EA 4508, UPE, 77454 Marne-la-Vallée, France
| | | | | | | | | | | |
Collapse
|
4
|
|
5
|
Narayana B, Veena K, Ashwani K, Shetty DN. New reagents for the spectrophotometric determination of ranitidine hydrochloride. ECLÉTICA QUÍMICA 2010. [DOI: 10.1590/s0100-46702010000300010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
6
|
Radjenović J, Sirtori C, Petrović M, Barceló D, Malato S. Characterization of intermediate products of solar photocatalytic degradation of ranitidine at pilot-scale. CHEMOSPHERE 2010; 79:368-376. [PMID: 20207392 DOI: 10.1016/j.chemosphere.2010.02.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2009] [Revised: 02/05/2010] [Accepted: 02/05/2010] [Indexed: 05/28/2023]
Abstract
In the present study the mechanisms of solar photodegradation of H(2)-receptor antagonist ranitidine (RNTD) were studied in a well-defined system of a pilot plant scale Compound Parabolic Collector (CPC) reactor. Two types of heterogeneous photocatalytic experiments were performed: catalysed by titanium-dioxide (TiO(2)) semiconductor and by Fenton reagent (Fe(2+)/H(2)O(2)), each one with distilled water and synthetic wastewater effluent matrix. Complete disappearance of the parent compounds and discreet mineralization were attained in all experiments. Furthermore, kinetic parameters, main intermediate products, release of heteroatoms and formation of carboxylic acids are discussed. The main intermediate products of photocatalytic degradation of RNTD have been structurally elucidated by tandem mass spectrometry (MS(2)) experiments performed at quadrupole-time of flight (QqToF) mass analyzer coupled to ultra-performance liquid chromatograph (UPLC). RNTD displayed high reactivity towards OH radicals, although a product of conduction band electrons reduction was also present in the experiment with TiO(2). In the absence of standards, quantification of intermediates was not possible and only qualitative profiles of their evolution could be determined. The proposed TiO(2) and photo-Fenton degradation routes of RNTD are reported for the first time.
Collapse
Affiliation(s)
- Jelena Radjenović
- Department of Environmental Chemistry, IDAEA-CSIC, c/Jordi Girona 18-26, 08034 Barcelona, Spain
| | | | | | | | | |
Collapse
|
7
|
Ashiru DAI, Patel R, Basit AW. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 860:235-40. [PMID: 18006395 DOI: 10.1016/j.jchromb.2007.10.029] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2007] [Revised: 10/07/2007] [Accepted: 10/17/2007] [Indexed: 10/22/2022]
Abstract
A validated, simple and universal HPLC-UV method for the determination of cimetidine, famotidine, nizatidine and ranitidine in human urine is presented. This is the first single HPLC method reported for the analysis of all four H(2) antagonists in human biological samples. This method was also utilized for the analysis of ranitidine and its metabolites in human urine. All calibration curves showed good linear regression (r(2)>0.9960) within test ranges. The method showed good precision and accuracy with overall intra- and inter-day variations of 0.2-13.6% and 0.2-12.1%, respectively. Separation of ranitidine and its metabolites using this assay provided significantly improved resolution, precision and accuracy compared to previously reported methods. The assay was successfully applied to a human volunteer study using ranitidine as the model compound.
Collapse
Affiliation(s)
- Diane A I Ashiru
- Department of Pharmaceutics, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | | | | |
Collapse
|
8
|
Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. JAPANESE JOURNAL OF PHARMACOLOGY 2000; 84:213-20. [PMID: 11128045 DOI: 10.1254/jjp.84.213] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Rat and human liver microsomes oxidized ranitidine to its N-oxide (66-76%) and S-oxide (13-18%) and desmethylranitidine (12-16%). N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%. Recombinant FMO isozymes like FMO1, FMO2, FMO3 and FMO5 produced 39, 79, 2180 and 4 ranitinine N-oxide and 45, 0, 580 and 280 ranitinine S-oxide pmol x min(-1) x nmol(-1) FMO, respectively. Desmethyranitinine was not produced by recombinant FMOs. Production of desmethylranitidine by rat and human liver microsomes was inhibited by tranylcypromine, a-naphthoflavon and quinidine, which are known to inhibit CYP2C19, 1A2 and 2D6, repectively. FMO3, the major form in adult liver, produced both ranitidine N- and S-oxides at a 4 to 1 ratio. FMO1, expressed primarily in human kidney, was 55- and 13-fold less efficient than the hepatic FMO3 in producing ranitidine N- and S-oxides, respectively. FMO2 and FMO5, although expressed slightly in human liver, kidney and lung, were not efficient producers of ranitidine N- and S-oxides. Thus, urinary contents of ranitidine N-oxide can be used as the in vivo probe to determine the hepatic FMO3 activity.
Collapse
Affiliation(s)
- W G Chung
- Department of Pharmacology and Medicinal Toxicology Research Center, Inha University, Inchon, Korea
| | | | | | | | | |
Collapse
|
9
|
Kang JH, Chung WG, Lee KH, Park CS, Kang JS, Shin IC, Roh HK, Dong MS, Baek HM, Cha YN. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. PHARMACOGENETICS 2000; 10:67-78. [PMID: 10739174 DOI: 10.1097/00008571-200002000-00009] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A non-invasive urine analysis method to determine the in-vivo flavin-containing mono-oxygenase (FMO) activity catalysing N-oxidation of ranitidine (RA) was developed and used to phenotype a Korean population. FMO activity was assessed by the molar concentration ratio of RA and RANO in the bulked 8 h urine. This method was used to determine the FMO phenotypes of 210 Korean volunteers (173 men and 37 women, 110 nonsmokers and 100 smokers). Urinary RA/RANO ratio, representing the metabolic ratio and the reciprocal index of FMO activity, ranged from 5.67-27.20 (4.8-fold difference) and was not different between men and women (P = 0.76) or between smokers and nonsmokers (P = 0.50). The frequencies of RA/RANO ratios were distributed in a trimodal fashion. Among the 210 Korean subjects, 93 (44.3%) were fast metabolizers, 104 (49.5%) were intermediate metabolizers and 13 (6.2%) were slow metabolizers. Subsequently, the relationship between the ranitidine N-oxidation phenotypes and FMO3 genotypes, determined by the presence of two previously identified mutant alleles (Glu158Lys: FMO3/Lys158 and Glu308Gly: FMO3/Gly308 alleles) commonly found in our Korean population was examined. The results showed that subjects who were homozygous and heterozygous for either one or both of the FMO3/Lys158 and FMO3/Gly308 mutant alleles had significantly lower in-vivo FMO activities than those with homozygous wild-type alleles (FMO3/Glu158 and FMO3/Glu308) (P < 0.001, Mann-Whitney U-test). Furthermore, the FMO activities of subjects with either FMO3/Lys158 or FMO3/Gly308 mutant alleles were almost identical to those having both FMO3 mutant alleles (FMO3/Lys158 and FMO3/Gly308). These two mutant alleles located, respectively, at exons 4 and 7 in the FMO3 gene appeared to be strongly linked by cis-configuration in Koreans. Therefore, we concluded that presence of FMO3/Lys158 and FMO3/Gly308 mutant alleles in FMO3 gene is responsible for the low ranitidine N-oxidation (FMO3 activity) in our Korean population.
Collapse
Affiliation(s)
- J H Kang
- Department of Pharmacology and Toxicology, College of Medicine, Inha University, Inchon, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Davis RL, Quenzer RW, Bozigian HP, Warner CW. Pharmacokinetics of ranitidine in morbidly obese women. DICP : THE ANNALS OF PHARMACOTHERAPY 1990; 24:1040-3. [PMID: 2275223 DOI: 10.1177/106002809002401101] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The pharmacokinetics of a single dose of ranitidine 50 mg iv were determined in ten normal-weight and ten morbidly obese (greater than 90 percent ideal body weight) age-matched female subjects. No significant difference between normal and obese subjects was found in ranitidine peak serum concentration, volume of distribution, clearance, and elimination rate constant. Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs. 0.33 L/h/kg, respectively; p less than 0.001) but not when normalized to ideal body weight (1.65 vs. 1.45 L/kg and 0.68 vs. 0.59 L/h/kg). We conclude that obese patients receiving ranitidine therapy should be treated with standard dosages or dosages based on ideal body weight.
Collapse
Affiliation(s)
- R L Davis
- College of Pharmacy, University of New Mexico, Albuquerque 87131
| | | | | | | |
Collapse
|
11
|
Abstract
In reviewing the analytical methods for the analysis of anti-ulcer drugs we observed an increase in the utilization of solid-phase extraction techniques, though the traditional liquid-liquid methods are still predominant. Liquid chromatographic techniques are employed more than gas chromatographic methods which reflects the general trend in chromatographic analysis for analytes in the nanogram range. We foresee a continued increase in the use of solid-phase extraction methodology (automated or otherwise) due to the potential for dramatic decreases in extraction times, cost and significant enhancement of extraction efficiency. Because the therapeutic concentrations of these drugs tend to be in the low nanogram range in plasma and the current trend in drug development is toward more potent agents, we anticipate the application of more sensitive liquid chromatographic detection techniques such as electrochemical and chemiluminescence detection to overcome the limitations of currently used technology.
Collapse
|
12
|
Tomer KB, Parker CE. Biochemical applications of liquid chromatography-mass spectrometry. JOURNAL OF CHROMATOGRAPHY 1989; 492:189-221. [PMID: 2670991 DOI: 10.1016/s0378-4347(00)84469-2] [Citation(s) in RCA: 68] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The current state-of-the-art liquid chromatography-mass spectrometry (LC-MS) is reviewed with particular attention to biomedical applications. The most common LC-MS interface designs are described and compared. These interfaces include transport, direct liquid introduction, thermospray, atmospheric pressure ionization, monodisperse aerosol generation, open-tubular LC and continuous-flow fast atom bombardment. The relative sensitivities of the techniques are compared as much as possible, as well as their tendencies to induce thermal decomposition of the sample. Applications of these various interface types to a variety of biomedically important compound classes, including peptides, nucleotides, steroids, lipids, carbohydrates, xenobiotic metabolites and drugs, are also reviewed.
Collapse
Affiliation(s)
- K B Tomer
- Laboratory of Molecular Biophysics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709
| | | |
Collapse
|
13
|
Prueksaritanont T, Sittichai N, Prueksaritanont S, Vongsaroj R. Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY 1989; 490:175-85. [PMID: 2760148 DOI: 10.1016/s0378-4347(00)82772-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A sensitive high-performance liquid chromatographic method was developed for the simultaneous determination of ranitidine and its metabolites, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, in human plasma and urine. For the plasma analysis, 1-ml plasma samples spiked with phenylpyramidol as the internal standard were extracted at basic pH with acetonitrile-ethyl acetate (3:2, v/v). After evaporation and reconstitution, the samples were chromatographed on a cation-exchange column, with a mobile phase of 0.1 M sodium acetate buffer (pH 5)-acetonitrile-tetrahydrofuran (56.5:36:7.5, v/v) and ultraviolet detection at 320 nm. The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively. For the urine analysis, a simple deproteinization with an equal volume of acetonitrile was satisfactory for sample preparation. The applicability of this method for the pharmacokinetic study of ranitidine following oral administration was demonstrated.
Collapse
Affiliation(s)
- T Prueksaritanont
- Drug Analysis Division, Department of Medical Sciences, Yod-se, Bangkok
| | | | | | | |
Collapse
|
14
|
|
15
|
Lant MS, Martin LE, Oxford J. Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry. J Chromatogr A 1985; 323:143-52. [PMID: 4008551 DOI: 10.1016/s0021-9673(01)90379-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Reversed-phase high-performance liquid chromatography systems for the separation of ranitidine and its metabolites ranitidine-N-oxide, ranitidine-S-oxide, and desmethylranitidine have been developed for use in high-performance liquid chromatography-mass spectrometry. A direct liquid introduction-high-performance liquid chromatography-mass spectrometry system to analyse qualitatively and quantitatively solutions containing ranitidine and its metabolites by reversed-phase chromatography is described. A sample of urine collected from a subject given an oral dose of 75 mg of ranitidine and 75 mg of tris-deuterated ranitidine was analysed by this system. Ranitidine and its metabolites were identified by the ion doublets in the mass spectra which were 3 a.m.u. apart.
Collapse
|
16
|
Abstract
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine on a molar basis in inhibiting stimulated gastric acid secretion. Clinical studies have demonstrated that ranitidine is as effective as cimetidine and is similarly well tolerated. Based on available literature (approximately 700 publications), this article reviews the pharmacology, safety profile, and clinical efficacy of ranitidine in duodenal ulcers and gastric hypersecretory conditions.
Collapse
|
17
|
Bell JA, Bradbury A, Martin LE, Tanner RJ. Applications of high-voltage paper electrophoresis for the characterization of drug metabolites. Xenobiotica 1981; 11:841-7. [PMID: 6123201 DOI: 10.3109/00498258109045321] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
1. The application of high-voltage paper electrophoresis (h.v.p.e.) to the identification of drug metabolites in urine and bile has been investigated. 2. The major urinary metabolite of [3H]salbutamol in man had an electrophoretic mobility indicative of a sulphate ester. 3. A metabolite of [14C]ranitidine present in rat bile was shown to contain an ionized group with a pKa corresponding to a carboxylic acid. 4. The electrophoretic mobility-pH profile of a metabolite of radiolabelled N"-cyano-N-[2-[5-(dimethylaminomethyl)-2-furanylmethylthio]ethyl]-N-methylguanidine (14C-AH 18801) excreted in dog urine suggested that oxidation of the tertiary amine group of the compound had occurred. 5. H.v.p.e. provided valuable information on the structure of both phases I and phase II metabolites at a stage when the material was insufficiently pure for identification by other techniques.
Collapse
|